UK markets close in 8 hours 28 minutes
  • FTSE 100

    7,765.15
    0.00 (0.00%)
     
  • FTSE 250

    20,035.39
    0.00 (0.00%)
     
  • AIM

    869.24
    +3.83 (+0.44%)
     
  • GBP/EUR

    1.1384
    -0.0020 (-0.18%)
     
  • GBP/USD

    1.2377
    -0.0018 (-0.14%)
     
  • BTC-GBP

    19,113.74
    +266.22 (+1.41%)
     
  • CMC Crypto 200

    536.18
    +19.17 (+3.71%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • CRUDE OIL

    78.95
    -0.73 (-0.92%)
     
  • GOLD FUTURES

    1,939.80
    -5.80 (-0.30%)
     
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,030.04
    -658.86 (-2.90%)
     
  • DAX

    15,150.03
    +17.23 (+0.11%)
     
  • CAC 40

    7,097.21
    +1.22 (+0.02%)
     

Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

ReportLinker
ReportLinker

Summary. Type 2 Diabetes Mellitus, or T2D for short, refers to a defect in insulin secretion and sensitivity, whereby the ?-cells in the pancreas fail to secrete sufficient amounts of insulin and cells fail to uptake adequate amounts of insulin due to loss of sensitivity, commonly referred to as insulin resistance.

New York, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029" - https://www.reportlinker.com/p06382999/?utm_source=GNW
The dysfunction of pancreatic ?-cells is thought to be caused by a defect in their signaling, resulting in raised blood sugar (hypoglycemia), which over time leads to multiple comorbidities requiring continuous medical vigilance.

Many of the current therapies for T2D are unable to alter the disease’s natural course, with glycemic control deteriorating over time, resulting in complex treatment regimens

New therapies entering the market will be a main driver of growth, with recently launched GLP-1RA Rybelsus (oral semaglutide) is likely to obtain a large share of the non-insulin T2D drug market and biosimilar and oral insulins are likely to obtain a large market share from their costly branded originators.Other major drivers for the T2D market are the increasing prevalence of obesity and the increasing prevalence of cardiovascular and kidney disease .

Based on epidemiological analysis , the number of diagnosed prevalent cases of T2D will grow 25.93% over the forecast period, at an AGR of 2.3%, from 171,547,536 cases in 2019 to 216,029,212 cases by 2029 across the nine major pharmaceutical markets covered in this report, the US, 5EU (France, Germany, Italy, Spain and UK), Japan, India and China.

The analyst projects that the marketplace for T2D within the 9MM will grow from $45bn in 2019 at a compound annual growth rate (CAGR) of 11.5% to $136.2B by 2029. In particular, The analyst expects US market will contribute the most to the antidiabetic market’s growth, contributing sales in $24.7B sales in 2019 (54% of the global antidiabetic market) and $66B in 2029 (48.5% of the global antidiabetic market).

In terms of the current treatment landscape, the consensus among interviewed physicians was that although they have a number of efficacious treatment options at their disposal, there are still patients that remain unable to achieve optimal glycemic control, address insulin resistance and reverse or slow the decline in ?-cell function.Additionally, KOLs interviewed highlighted the lack of treatment options for patients with T2D and complex comorbidities such as cardiorenal disease, an extremely important unmet need.

Another major issue mentioned is the cost of insulin treatment, with a strong need for controls on insulin drug pricing and a fair price for biosimilar/interchangeable insulins.
In addition, drug classes across the T2D marketplace often have poor side-effect profiles and there is an urgent need to broaden the drugs available to T2D patients to allow for safer and more tailored therapies. Despite a number of drugs currently in development, research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the T2D market.

Key Highlights
- The proportion of people at risk of developing T2D is expected to increase over the 10-year forecast period due to an increased life expectancy coupled with rapid socioeconomic change, increased prevalence of obesity and the increased prevalence of cardiovascular (CV) disease
- The potential launch of 10 late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, five of these drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
- Cardiorenal disease is being increasingly recognized in clinical practice and there has been a renewed interest among the medical community to understand the pathophysiological mechanisms underpinning its pathogenesis.
- Despite the plethora of therapies currently available to T2D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for patients unable to achieve optimal glycemic control.

KEY QUESTIONS ANSWERED

Despite the existence of numerous well-established treatment options in the T2D space, a few—yet significant—unmet needs remain.
- Which unmet needs are the most pressing in the 9MM?
- Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
The T2D market has been overcrowded by drug developers launching ‘Me-Too’ therapies for many years, though more recently, clinical development activity has resulted in more innovative treatments
- What are the most promising late-stage candidates and how much in sales are they expected to generate over the forecast period?
- What do KOLs say about their clinical and commercial positioning?
T2D remains a highly prevalent condition, and there are many new and emerging players entering the space, as well as more established companies developing novel therapies
- Which companies have been leading the way, historically?
- What new companies are emerging in the space?

Scope
- Overview of T2D: including epidemiology, disease etiology and management.
- Topline T2D drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, India and China over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global type 2 diabetes market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global type 2 diabetes therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06382999/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001